Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.

Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.

Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.

Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.

Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.

Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.

Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.

Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.

Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.

Biocytogen, an emerging pharmaceutical technology company, announced today that it has completed a new round of funding worth tens of millions of dollars, jointly led by Lake Bleu Capital, China Pinnacle Equity Management, Octagon Capital and OrbiMed.